Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Extension of Dalfampridine-ER for Walking Deficits in Chronic Post-Ischemic Stroke
NCT02422940Phase 3Terminated
- Sponsor
- Acorda Therapeutics
- Start
- Apr 2015
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of dalfampridine in ischemic stroke, sponsored by Acorda Therapeutics. Started Apr 2015; status: terminated.
02
Drugs
dalfampridine
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT02422940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02422940.